While lower-count MBL almost never progresses to CLL, significant-rely MBL progresses to CLL requiring therapy in a level of 1% to two% per annum. Higher-rely MBL is distinguished from Rai 0 CLL depending on whether or not the B-cell count is over or underneath five × 109/L. Whilst people today with the two higher-rely MBL and CLL Rai phase 0 are